Release Date: 12 July 2024
At present, four bispecific antibodies are undergoing regulatory review, with all four under evaluation by the FDA, and two also being reviewed by the EMA. This diverse pipeline included candidates targeting both hematolo...
Release Date: 12 July 2024
Bispecific antibodies present unparalleled opportunities for pioneering first-in-class therapies, exemplified by Tarlatamab from Amgen. As the first bispecific antibody targeting DLL3, Tarlatamab represents a groundbreaki...
Release Date: 12 July 2024
Reimbursement for bispecific antibodies is a multifaceted process that involves coverage under various healthcare plans. Government plans, such as Medicare and Medicaid, often provide reimbursement for approved bispecific...
Release Date: 12 July 2024
The development of bispecific antibodies has been propelled by the use of innovative platform technologies, such as BiTE and ADAPTIR, which streamline and optimize the creation of these complex therapeutics. These platfor...
Release Date: 12 July 2024
The need for bispecific antibodies is underscored by the complex and heterogeneous nature of diseases, particularly cancer and immune disorders. Traditional therapies often fall short in effectively targeting these condit...
Release Date: 12 July 2024
The market for bispecific antibodies is characterized by the presence of several major market players driving innovation and shaping the industry landscape. Leading biopharmaceutical companies such as Roche, Genmab, and A...
Release Date: 12 July 2024
The future of the bispecific antibodies market is poised for dynamic growth and innovation. As research continues to unveil the therapeutic potential of bispecific antibodies across diverse diseases areas, including oncology, autoimmune disorders and...
Release Date: 12 July 2024
At present, it is estimated that over 700 bispecific antibodies are in development, with a majority of these being in preclinical development, followed by those still under research. Bispecific antibodies for solid cancer...
Release Date: 12 July 2024
In 2023, the global bispecific antibodies market witnessed notable trends shaping its landscape. The US maintained its lead in regional sales, highlighting its critical role in driving market growth. Furthermore, the four...
Release Date: 16 May 2024
During first 3 months of 2024 bispecific antibodies sales in USA surpased USD 1.5 Billion and accounted for dominant share in global bispecific antibodies sales.
Release Date: 16 May 2024
Vabysmo saswittnesed postive outlook during first quarter of 2024. Vabysmo sales surpassed USD 900 Million accounting for more than 35% of global bispecific antibodi...
Release Date: 16 May 2024
Hemlibra sales surpased USD 1 Billion during first 3 months of 2024.Hemlibra accounted for more than 40% of global bispecific antibodies sales during first 3 months of 2024.
Release Date: 16 May 2024
Global Bispecific Antibodies sales surpassed USD 2.40 Billion during Q1 2024. More than 60% of sales came from US market. In previous year (2023), global bispecific antibodies sales surpassed USD 8 Billion.
Release Date: 14 May 2024
In the realm of cancer treatment, the pursuit of new therapies is imperative to combat the relentless nature of the disease and address the limitations of current options. Existing treatments often carry debilitating side...
Release Date: 29 February 2024
Download Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report: